{
    "ticker": "CYCC",
    "name": "Cyclacel Pharmaceuticals, Inc.",
    "description": "Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative medicines for the treatment of cancer and other serious diseases. Founded in 1996 and headquartered in Durham, North Carolina, Cyclacel is dedicated to advancing therapies that target critical mechanisms of cancer biology. The company\u2019s lead product candidates include oral inhibitors of cyclin-dependent kinases (CDKs), which are essential in regulating cell division and have shown promise in treating various malignancies. Cyclacel's proprietary technology platform leverages its expertise in cell cycle regulation and cancer biology to develop therapies that can potentially improve patient outcomes. The company is also exploring combinations with existing therapies to enhance efficacy and address resistance mechanisms in cancer treatment. Cyclacel is committed to scientific innovation and is actively engaged in clinical trials to evaluate the safety and efficacy of its drug candidates, aiming to bring new therapeutic options to patients with unmet medical needs. The company collaborates with academic institutions and industry partners to further its research and development efforts, reflecting its mission to transform cancer care through groundbreaking treatments.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Durham, North Carolina, USA",
    "founded": "1996",
    "website": "https://www.cyclacel.com",
    "ceo": "Spencer L. B. P. M. K. M. M. J. W. B. H. A. D. W. M. C.",
    "social_media": {
        "twitter": "https://twitter.com/Cyclacel",
        "linkedin": "https://www.linkedin.com/company/cyclacel-pharmaceuticals"
    },
    "investor_relations": "https://ir.cyclacel.com",
    "key_executives": [
        {
            "name": "Spencer L. B. P. M. K. M. M. J. W. B. H. A. D. W. M. C.",
            "position": "CEO"
        },
        {
            "name": "James A. N. C.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Drugs",
            "products": [
                "CYC065",
                "CYC140"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cyclacel Pharmaceuticals, Inc. | Innovative Cancer Treatments",
        "meta_description": "Cyclacel Pharmaceuticals is focused on developing innovative therapies for cancer treatment. Learn about their clinical-stage drug candidates and commitment to cancer care.",
        "keywords": [
            "Cyclacel",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "Innovative Medicines",
            "CDK Inhibitors"
        ]
    },
    "faq": [
        {
            "question": "What does Cyclacel Pharmaceuticals focus on?",
            "answer": "Cyclacel Pharmaceuticals focuses on developing innovative medicines for cancer treatment."
        },
        {
            "question": "Where is Cyclacel headquartered?",
            "answer": "Cyclacel is headquartered in Durham, North Carolina, USA."
        },
        {
            "question": "What are Cyclacel's lead product candidates?",
            "answer": "Cyclacel's lead product candidates include CYC065 and CYC140, which are oral inhibitors of cyclin-dependent kinases."
        },
        {
            "question": "When was Cyclacel founded?",
            "answer": "Cyclacel was founded in 1996."
        }
    ],
    "competitors": [
        "CLVS",
        "NDAQ",
        "IMMU",
        "ADMA"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "MRNA"
    ]
}